| 1 | parallel | 5,919 |
| 2 | placebo-control | 66 |
| 3 | before/after | 56 |
| 4 | side-by-side | 49 |
| 5 | diagnosis-related | 47 |
| 6 | counter-balanced | 44 |
| 7 | high-mobility | 36 |
| 8 | delayed-start | 29 |
| 9 | one-arm | 22 |
| 10 | baseline-hb | 17 |
| 11 | s/as01e | 14 |
| 12 | hs+hes | 11 |
| 13 | intervention-control | 11 |
| 14 | mein | 10 |
| 15 | three-cycle | 10 |
| 16 | mid-trial | 9 |
| 17 | regul8 | 9 |
| 18 | imrt-tp | 8 |
| 19 | late-treatment | 8 |
| 20 | multiplayer | 8 |
| 21 | non-antisiphon | 8 |
| 22 | non-crossover | 8 |
| 23 | propofol/fentanyl | 8 |
| 24 | afo-wearing | 7 |
| 25 | jinsane | 7 |
| 26 | no-prompt | 7 |
| 27 | p+en | 7 |
| 28 | polycan | 7 |
| 29 | spi-guided | 7 |
| 30 | unicore | 7 |
| 31 | clinician-initiated | 6 |
| 32 | flute | 6 |
| 33 | half-side | 6 |
| 34 | hp-cvvh | 6 |
| 35 | lancefield | 6 |
| 36 | propofol/dexmedetomidine | 6 |
| 37 | silica-treated | 6 |
| 38 | thermotolerance/hyperthermia | 6 |
| 39 | trials.no | 6 |
| 40 | yc-1+thermotolerance/hyperthermia | 6 |
| 41 | ydgdr-treated | 6 |
| 42 | bis-titrated | 5 |
| 43 | cresco | 5 |
| 44 | gcae-treated | 5 |
| 45 | gcea | 5 |
| 46 | non-oh | 5 |
| 47 | noncrossover | 5 |
| 48 | phono | 5 |
| 49 | pn+gln | 5 |
| 50 | tcd-treated | 5 |
| 51 | toggleloc | 5 |
| 52 | wait-control | 5 |
| 53 | α1,3gti-3 | 5 |
| 54 | 20-patient | 4 |
| 55 | all-male | 4 |
| 56 | hhpg-19k | 4 |
| 57 | hul+17-aag | 4 |
| 58 | low-radiation | 4 |
| 59 | single-cleansing | 4 |
| 60 | tibotec-virco | 4 |
| 61 | trials-the | 4 |
| 62 | two-parallel | 4 |
| 63 | v-pl-v | 4 |
| 64 | within-food | 4 |
| 65 | 3dcrt+ht | 3 |
| 66 | anodal-so | 3 |
| 67 | ar79 | 3 |
| 68 | cd163high | 3 |
| 69 | control-trial | 3 |
| 70 | cystitis-injury | 3 |
| 71 | dexmedetomidine-atropine | 3 |
| 72 | dha+ | 3 |
| 73 | equivalence/noninferiority | 3 |
| 74 | ferrer | 3 |
| 75 | fixed-size | 3 |
| 76 | flp-treated | 3 |
| 77 | formamido | 3 |
| 78 | gh/hmg/gnrhant | 3 |
| 79 | gth | 3 |
| 80 | high-reward | 3 |
| 81 | low-protein/high-gi | 3 |
| 82 | mtx-vimang | 3 |
| 83 | nhpc | 3 |
| 84 | non-ams | 3 |
| 85 | non-cin | 3 |
| 86 | non-haart | 3 |
| 87 | non-parallel | 3 |
| 88 | nonconcomitant | 3 |
| 89 | o'-carboxylate | 3 |
| 90 | paired-matched | 3 |
| 91 | parallel- | 3 |
| 92 | pc-3/smac | 3 |
| 93 | phentolaminum | 3 |
| 94 | pra+mica+ | 3 |
| 95 | qrhx+mtx | 3 |
| 96 | regicor2000 | 3 |
| 97 | sex-treatment | 3 |
| 98 | smp/gmp/g60 | 3 |
| 99 | sulfadiazine-trimethoprim | 3 |
| 100 | t2dm-t | 3 |
| 101 | tmz-rt | 3 |
| 102 | vthr | 3 |
| 103 | wake-sleep | 3 |
| 104 | zn-treated | 3 |
| 105 | ≃ | 3 |
| 106 | 'dialogue | 2 |
| 107 | 2'/3'-o-acetyl | 2 |
| 108 | 2-parallel | 2 |
| 109 | 3-chloro-2-hydroxypropyl | 2 |
| 110 | 31/172 | 2 |
| 111 | 5-fu-sol | 2 |
| 112 | ac-ps-treated | 2 |
| 113 | acetaminophen/oxycodone | 2 |
| 114 | ad-ace2+a779 | 2 |
| 115 | analogue-based | 2 |
| 116 | booklet-only | 2 |
| 117 | bw-bmi | 2 |
| 118 | chair-rises | 2 |
| 119 | cidr-heatsynch | 2 |
| 120 | cma-coc | 2 |
| 121 | co-immunizations | 2 |
| 122 | cryptorchidism-induced | 2 |
| 123 | cycle/ue-ex | 2 |
| 124 | dienogest-coc | 2 |
| 125 | e2997 | 2 |
| 126 | equally-sized | 2 |
| 127 | faculty-moderated | 2 |
| 128 | fxc | 2 |
| 129 | ganirelix-mf | 2 |
| 130 | ginger-receiving | 2 |
| 131 | heterokaryon | 2 |
| 132 | hfd+haepa | 2 |
| 133 | himawari | 2 |
| 134 | hippopotamus | 2 |
| 135 | hot-treatment | 2 |
| 136 | htlv-1-asymptomatic | 2 |
| 137 | hydrofibers | 2 |
| 138 | idpn+jpzdd | 2 |
| 139 | im/pm | 2 |
| 140 | india.the | 2 |
| 141 | information-support | 2 |
| 142 | inter-observers | 2 |
| 143 | internal-fire+phlegm-dampness+blood-stasis | 2 |
| 144 | irbesatan | 2 |
| 145 | keyswitch | 2 |
| 146 | khr | 2 |
| 147 | manual-driven | 2 |
| 148 | match-pair | 2 |
| 149 | matki-containing | 2 |
| 150 | medel | 2 |
| 151 | median-dose | 2 |
| 152 | menicare | 2 |
| 153 | meta-meth-oxy | 2 |
| 154 | mixed-disability | 2 |
| 155 | morphine-benzedrine | 2 |
| 156 | no-boost | 2 |
| 157 | no-pop | 2 |
| 158 | non-pemetrexed-containing | 2 |
| 159 | not-improved | 2 |
| 160 | o1a2 | 2 |
| 161 | o2a1 | 2 |
| 162 | osteo-induced | 2 |
| 163 | p1032 | 2 |
| 164 | pa-etched | 2 |
| 165 | paliperidone-er | 2 |
| 166 | pleg | 2 |
| 167 | pra+mica- | 2 |
| 168 | practica | 2 |
| 169 | pro-amed | 2 |
| 170 | prp-plus | 2 |
| 171 | remi-pro-rocu | 2 |
| 172 | residential/outpatient | 2 |
| 173 | strech | 2 |
| 174 | sunitinib-containing | 2 |
| 175 | supplement-only | 2 |
| 176 | thecontrol | 2 |
| 177 | therapy-withdrawal | 2 |
| 178 | trenching | 2 |
| 179 | trichothiodystrophy | 2 |
| 180 | undergraduate-entry | 2 |
| 181 | unitedhealth | 2 |
| 182 | unstirred | 2 |
| 183 | v-v-pl | 2 |
| 184 | w-i/r | 2 |
| 185 | walk-across | 2 |
| 186 | '26-week | 1 |
| 187 | '4-week | 1 |
| 188 | 'club | 1 |
| 189 | 'inma | 1 |
| 190 | 0.05-mg | 1 |
| 191 | 2-hy-droxy-3-methyl-benzyl | 1 |
| 192 | 2-methoxy-5-chlorobenzyl | 1 |
| 193 | 2-methoxy/ethoxycarbonyl | 1 |
| 194 | 3-chloro-4-methoxybenzyl | 1 |
| 195 | 3-chloro-6-hy-droxy-2,4-di-methyl-benzyl | 1 |
| 196 | 3-ketone | 1 |
| 197 | 3-methylpiperazine | 1 |
| 198 | 3-parallel | 1 |
| 199 | 35-patient | 1 |
| 200 | 4-parallel | 1 |
| 201 | 5-htt-expressing | 1 |
| 202 | 5-nitro | 1 |
| 203 | 6-electron | 1 |
| 204 | 9-aryl | 1 |
| 205 | 9-patient | 1 |
| 206 | 9a-b | 1 |
| 207 | abciximab/ufh | 1 |
| 208 | acei-3d+mi | 1 |
| 209 | adherence-intervention | 1 |
| 210 | age-orientated | 1 |
| 211 | anbainou | 1 |
| 212 | and-phenylpentyl | 1 |
| 213 | anti-vefgr1 | 1 |
| 214 | balanced-parallel | 1 |
| 215 | bdf/f | 1 |
| 216 | before-implementation | 1 |
| 217 | benzyl-amino | 1 |
| 218 | betwen | 1 |
| 219 | bioconjugatable | 1 |
| 220 | biologics-treated | 1 |
| 221 | bipartisan | 1 |
| 222 | bite-wafer | 1 |
| 223 | bromo-phenyl-piperazine | 1 |
| 224 | bt-only | 1 |
| 225 | bushenhuatanyizhi | 1 |
| 226 | cad-ela | 1 |
| 227 | carbamoylheptyl | 1 |
| 228 | catheter-size | 1 |
| 229 | celecoxib-containing | 1 |
| 230 | ch2or | 1 |
| 231 | chemotherapyalone | 1 |
| 232 | clinic-invitation | 1 |
| 233 | clomi-phene | 1 |
| 234 | clopdogrel | 1 |
| 235 | clp+xbj | 1 |
| 236 | cold/heat-repressed | 1 |
| 237 | colinox® | 1 |
| 238 | combined-exercise-training | 1 |
| 239 | conhr | 1 |
| 240 | control-matched | 1 |
| 241 | control_2 | 1 |
| 242 | controlled-point | 1 |
| 243 | counselor-facilitated | 1 |
| 244 | country-race | 1 |
| 245 | crf-treated | 1 |
| 246 | crt-only | 1 |
| 247 | cs-ps-treated | 1 |
| 248 | cycloalkenyl | 1 |
| 249 | diabetes-bp | 1 |
| 250 | diabetes/metformin | 1 |
| 251 | diet-plus-resistance-training | 1 |
| 252 | difluorine | 1 |
| 253 | dimethoxymethyl | 1 |
| 254 | double-dose-statin | 1 |
| 255 | dox-intoxicated | 1 |
| 256 | epoxystearyl | 1 |
| 257 | equally-numbered | 1 |
| 258 | etc.sildenafil | 1 |
| 259 | experimenter-verbalization | 1 |
| 260 | ezetimib/simvastatin | 1 |
| 261 | flx/olz | 1 |
| 262 | forty-patient | 1 |
| 263 | galn/lps-treated | 1 |
| 264 | gcop | 1 |
| 265 | groups-r | 1 |
| 266 | gsd-treated | 1 |
| 267 | guanidyl | 1 |
| 268 | gutsy | 1 |
| 269 | h-nw | 1 |
| 270 | h-ob | 1 |
| 271 | h-ow | 1 |
| 272 | hf-10-week | 1 |
| 273 | high-performer | 1 |
| 274 | highest-dose-containing | 1 |
| 275 | hsp-negative | 1 |
| 276 | icd† | 1 |
| 277 | imatinib+ifn | 1 |
| 278 | ins+/-rsg | 1 |
| 279 | into- | 1 |
| 280 | inventory-morphine-benzedrine | 1 |
| 281 | ir+ng | 1 |
| 282 | ir+sa | 1 |
| 283 | iri+saline | 1 |
| 284 | isoflavones-berberine-treated | 1 |
| 285 | k-134-containing | 1 |
| 286 | karaya-saponin-treated | 1 |
| 287 | keto-carbonyl | 1 |
| 288 | l-trp-supplemented | 1 |
| 289 | linifanib-treated | 1 |
| 290 | long-detection | 1 |
| 291 | low-performer | 1 |
| 292 | low-toxin-contaminated | 1 |
| 293 | lps/mabtrem-1 | 1 |
| 294 | mallet-osteotomes | 1 |
| 295 | mdg-1-diabetic | 1 |
| 296 | medial-dose | 1 |
| 297 | mediterranean-diet | 1 |
| 298 | methane-sulfonamyl | 1 |
| 299 | methane-sulfonyl | 1 |
| 300 | methoxyimino | 1 |
| 301 | methylsulfamoyl | 1 |
| 302 | mi-untreated | 1 |
| 303 | mild-monotherapy | 1 |
| 304 | mim-only | 1 |
| 305 | min.each | 1 |
| 306 | mk-801+risperidone | 1 |
| 307 | mmvc | 1 |
| 308 | monofluoroalkyl | 1 |
| 309 | monophylogenetic | 1 |
| 310 | motivation/skills | 1 |
| 311 | mtx/res | 1 |
| 312 | multi-disciplinal | 1 |
| 313 | multi-single-specialty | 1 |
| 314 | n-dimethylaminophenyl | 1 |
| 315 | naf-treated | 1 |
| 316 | nch3 | 1 |
| 317 | ndg-treated | 1 |
| 318 | no-catheter-use | 1 |
| 319 | no-metformin | 1 |
| 320 | no-morbidity | 1 |
| 321 | no-pmdi | 1 |
| 322 | no-relaxant | 1 |
| 323 | no-rest | 1 |
| 324 | no-retransfusion | 1 |
| 325 | no-supply | 1 |
| 326 | nocardia-treatment | 1 |
| 327 | non-at | 1 |
| 328 | non-bisoprolol | 1 |
| 329 | non-cilostazol | 1 |
| 330 | non-drain | 1 |
| 331 | non-enalapril | 1 |
| 332 | non-gel | 1 |
| 333 | non-interview | 1 |
| 334 | non-microalbuminuria | 1 |
| 335 | non-niddk | 1 |
| 336 | non-postmature | 1 |
| 337 | non-ppv | 1 |
| 338 | non-sbo | 1 |
| 339 | non-taboo | 1 |
| 340 | nonpolymerized | 1 |
| 341 | nontamoxifen-containing | 1 |
| 342 | nontransported | 1 |
| 343 | normalisized | 1 |
| 344 | normo-trained | 1 |
| 345 | np-training | 1 |
| 346 | nvp/cbv | 1 |
| 347 | on-licensed | 1 |
| 348 | oral+vaginal | 1 |
| 349 | ovx+epi | 1 |
| 350 | oxygen-resuscitated | 1 |
| 351 | p-nsai | 1 |
| 352 | pantihose | 1 |
| 353 | peer-drinking | 1 |
| 354 | phenylhydrazido | 1 |
| 355 | phycocyanin-fed | 1 |
| 356 | pilates-exercise | 1 |
| 357 | placebo-precedence-treated | 1 |
| 358 | placebo-therapy | 1 |
| 359 | placebo/no-treatment | 1 |
| 360 | placebo/pseudo-placebo | 1 |
| 361 | po-po | 1 |
| 362 | poorest-risk | 1 |
| 363 | ppausal | 1 |
| 364 | practitioner-assisted | 1 |
| 365 | pravastatin-treatment | 1 |
| 366 | prescriptions-control | 1 |
| 367 | project-oriented | 1 |
| 368 | psychologist-assisted | 1 |
| 369 | quasi-control | 1 |
| 370 | quchi+fenglong | 1 |
| 371 | quchi+zhongwan+fenglong | 1 |
| 372 | r286-d96 | 1 |
| 373 | raltitrexed/oxaliplatin | 1 |
| 374 | rd-3d+mi | 1 |
| 375 | reduced-mastication | 1 |
| 376 | remi-pro-roc | 1 |
| 377 | residual-component | 1 |
| 378 | resistance-band-protocol | 1 |
| 379 | resource-building | 1 |
| 380 | retinopathy/aer | 1 |
| 381 | rixx4414 | 1 |
| 382 | rsv/pi-3-inoculated | 1 |
| 383 | s-apr-treated | 1 |
| 384 | saline-propofol | 1 |
| 385 | se/cd-treated | 1 |
| 386 | sealant-using | 1 |
| 387 | sec-amino | 1 |
| 388 | self-nominated | 1 |
| 389 | sham-sham-treated | 1 |
| 390 | sham‑surgery | 1 |
| 391 | silodosin-preceding | 1 |
| 392 | sinecod | 1 |
| 393 | slef-treatment | 1 |
| 394 | soy-po | 1 |
| 395 | statins-treated | 1 |
| 396 | stimuliv-treated | 1 |
| 397 | stonebreaker | 1 |
| 398 | sub-treatment | 1 |
| 399 | sulfo | 1 |
| 400 | sulphydril | 1 |
| 401 | tam-stratified | 1 |
| 402 | tamsulosin-preceding | 1 |
| 403 | telophase-like | 1 |
| 404 | temperature-recovery | 1 |
| 405 | tetra-fluoro-phenolate | 1 |
| 406 | thetreatment | 1 |
| 407 | thiopurine-exposed | 1 |
| 408 | three-parallel | 1 |
| 409 | tibolne | 1 |
| 410 | tigloyl | 1 |
| 411 | time-challenged | 1 |
| 412 | toxin-supplemented | 1 |
| 413 | traditional-reperfusion | 1 |
| 414 | treatment-formulation | 1 |
| 415 | treatment-order | 1 |
| 416 | tri-ethnic | 1 |
| 417 | trialon | 1 |
| 418 | trigone-only | 1 |
| 419 | tsv/clp | 1 |
| 420 | two-age-class | 1 |
| 421 | two-post | 1 |
| 422 | tza | 1 |
| 423 | umepamuenas | 1 |
| 424 | vitro/twins | 1 |
| 425 | voxel-wise-based | 1 |
| 426 | walking-exercise | 1 |
| 427 | wei-collateral | 1 |
| 428 | well-examined | 1 |
| 429 | well-maintained.patient | 1 |
| 430 | wellness-control | 1 |
| 431 | within-dose | 1 |
| 432 | ws070117-treated | 1 |
| 433 | yang-predominant | 1 |
| 434 | yin-predominant | 1 |
| 435 | yoga-and-exercise | 1 |
| 436 | zhongwan+fenglong | 1 |
| 437 | zlt-fed | 1 |
| 438 | β-blocker-3d+mi | 1 |
| 1 | '26-week | 1 |
| 2 | '4-week | 1 |
| 3 | 'club | 1 |
| 4 | 'dialogue | 2 |
| 5 | 'inma | 1 |
| 6 | 0.05-mg | 1 |
| 7 | 2'/3'-o-acetyl | 2 |
| 8 | 2-hy-droxy-3-methyl-benzyl | 1 |
| 9 | 2-methoxy-5-chlorobenzyl | 1 |
| 10 | 2-methoxy/ethoxycarbonyl | 1 |
| 11 | 2-parallel | 2 |
| 12 | 20-patient | 4 |
| 13 | 3-chloro-2-hydroxypropyl | 2 |
| 14 | 3-chloro-4-methoxybenzyl | 1 |
| 15 | 3-chloro-6-hy-droxy-2,4-di-methyl-benzyl | 1 |
| 16 | 3-ketone | 1 |
| 17 | 3-methylpiperazine | 1 |
| 18 | 3-parallel | 1 |
| 19 | 31/172 | 2 |
| 20 | 35-patient | 1 |
| 21 | 3dcrt+ht | 3 |
| 22 | 4-parallel | 1 |
| 23 | 5-fu-sol | 2 |
| 24 | 5-htt-expressing | 1 |
| 25 | 5-nitro | 1 |
| 26 | 6-electron | 1 |
| 27 | 9-aryl | 1 |
| 28 | 9-patient | 1 |
| 29 | 9a-b | 1 |
| 30 | abciximab/ufh | 1 |
| 31 | ac-ps-treated | 2 |
| 32 | acei-3d+mi | 1 |
| 33 | acetaminophen/oxycodone | 2 |
| 34 | ad-ace2+a779 | 2 |
| 35 | adherence-intervention | 1 |
| 36 | afo-wearing | 7 |
| 37 | age-orientated | 1 |
| 38 | all-male | 4 |
| 39 | analogue-based | 2 |
| 40 | anbainou | 1 |
| 41 | and-phenylpentyl | 1 |
| 42 | anodal-so | 3 |
| 43 | anti-vefgr1 | 1 |
| 44 | ar79 | 3 |
| 45 | balanced-parallel | 1 |
| 46 | baseline-hb | 17 |
| 47 | bdf/f | 1 |
| 48 | before-implementation | 1 |
| 49 | before/after | 56 |
| 50 | benzyl-amino | 1 |
| 51 | betwen | 1 |
| 52 | bioconjugatable | 1 |
| 53 | biologics-treated | 1 |
| 54 | bipartisan | 1 |
| 55 | bis-titrated | 5 |
| 56 | bite-wafer | 1 |
| 57 | booklet-only | 2 |
| 58 | bromo-phenyl-piperazine | 1 |
| 59 | bt-only | 1 |
| 60 | bushenhuatanyizhi | 1 |
| 61 | bw-bmi | 2 |
| 62 | cad-ela | 1 |
| 63 | carbamoylheptyl | 1 |
| 64 | catheter-size | 1 |
| 65 | cd163high | 3 |
| 66 | celecoxib-containing | 1 |
| 67 | ch2or | 1 |
| 68 | chair-rises | 2 |
| 69 | chemotherapyalone | 1 |
| 70 | cidr-heatsynch | 2 |
| 71 | clinic-invitation | 1 |
| 72 | clinician-initiated | 6 |
| 73 | clomi-phene | 1 |
| 74 | clopdogrel | 1 |
| 75 | clp+xbj | 1 |
| 76 | cma-coc | 2 |
| 77 | co-immunizations | 2 |
| 78 | cold/heat-repressed | 1 |
| 79 | colinox® | 1 |
| 80 | combined-exercise-training | 1 |
| 81 | conhr | 1 |
| 82 | control-matched | 1 |
| 83 | control-trial | 3 |
| 84 | control_2 | 1 |
| 85 | controlled-point | 1 |
| 86 | counselor-facilitated | 1 |
| 87 | counter-balanced | 44 |
| 88 | country-race | 1 |
| 89 | cresco | 5 |
| 90 | crf-treated | 1 |
| 91 | crt-only | 1 |
| 92 | cryptorchidism-induced | 2 |
| 93 | cs-ps-treated | 1 |
| 94 | cycle/ue-ex | 2 |
| 95 | cycloalkenyl | 1 |
| 96 | cystitis-injury | 3 |
| 97 | delayed-start | 29 |
| 98 | dexmedetomidine-atropine | 3 |
| 99 | dha+ | 3 |
| 100 | diabetes-bp | 1 |
| 101 | diabetes/metformin | 1 |
| 102 | diagnosis-related | 47 |
| 103 | dienogest-coc | 2 |
| 104 | diet-plus-resistance-training | 1 |
| 105 | difluorine | 1 |
| 106 | dimethoxymethyl | 1 |
| 107 | double-dose-statin | 1 |
| 108 | dox-intoxicated | 1 |
| 109 | e2997 | 2 |
| 110 | epoxystearyl | 1 |
| 111 | equally-numbered | 1 |
| 112 | equally-sized | 2 |
| 113 | equivalence/noninferiority | 3 |
| 114 | etc.sildenafil | 1 |
| 115 | experimenter-verbalization | 1 |
| 116 | ezetimib/simvastatin | 1 |
| 117 | faculty-moderated | 2 |
| 118 | ferrer | 3 |
| 119 | fixed-size | 3 |
| 120 | flp-treated | 3 |
| 121 | flute | 6 |
| 122 | flx/olz | 1 |
| 123 | formamido | 3 |
| 124 | forty-patient | 1 |
| 125 | fxc | 2 |
| 126 | galn/lps-treated | 1 |
| 127 | ganirelix-mf | 2 |
| 128 | gcae-treated | 5 |
| 129 | gcea | 5 |
| 130 | gcop | 1 |
| 131 | gh/hmg/gnrhant | 3 |
| 132 | ginger-receiving | 2 |
| 133 | groups-r | 1 |
| 134 | gsd-treated | 1 |
| 135 | gth | 3 |
| 136 | guanidyl | 1 |
| 137 | gutsy | 1 |
| 138 | h-nw | 1 |
| 139 | h-ob | 1 |
| 140 | h-ow | 1 |
| 141 | half-side | 6 |
| 142 | heterokaryon | 2 |
| 143 | hf-10-week | 1 |
| 144 | hfd+haepa | 2 |
| 145 | hhpg-19k | 4 |
| 146 | high-mobility | 36 |
| 147 | high-performer | 1 |
| 148 | high-reward | 3 |
| 149 | highest-dose-containing | 1 |
| 150 | himawari | 2 |
| 151 | hippopotamus | 2 |
| 152 | hot-treatment | 2 |
| 153 | hp-cvvh | 6 |
| 154 | hs+hes | 11 |
| 155 | hsp-negative | 1 |
| 156 | htlv-1-asymptomatic | 2 |
| 157 | hul+17-aag | 4 |
| 158 | hydrofibers | 2 |
| 159 | icd† | 1 |
| 160 | idpn+jpzdd | 2 |
| 161 | im/pm | 2 |
| 162 | imatinib+ifn | 1 |
| 163 | imrt-tp | 8 |
| 164 | india.the | 2 |
| 165 | information-support | 2 |
| 166 | ins+/-rsg | 1 |
| 167 | inter-observers | 2 |
| 168 | internal-fire+phlegm-dampness+blood-stasis | 2 |
| 169 | intervention-control | 11 |
| 170 | into- | 1 |
| 171 | inventory-morphine-benzedrine | 1 |
| 172 | ir+ng | 1 |
| 173 | ir+sa | 1 |
| 174 | irbesatan | 2 |
| 175 | iri+saline | 1 |
| 176 | isoflavones-berberine-treated | 1 |
| 177 | jinsane | 7 |
| 178 | k-134-containing | 1 |
| 179 | karaya-saponin-treated | 1 |
| 180 | keto-carbonyl | 1 |
| 181 | keyswitch | 2 |
| 182 | khr | 2 |
| 183 | l-trp-supplemented | 1 |
| 184 | lancefield | 6 |
| 185 | late-treatment | 8 |
| 186 | linifanib-treated | 1 |
| 187 | long-detection | 1 |
| 188 | low-performer | 1 |
| 189 | low-protein/high-gi | 3 |
| 190 | low-radiation | 4 |
| 191 | low-toxin-contaminated | 1 |
| 192 | lps/mabtrem-1 | 1 |
| 193 | mallet-osteotomes | 1 |
| 194 | manual-driven | 2 |
| 195 | match-pair | 2 |
| 196 | matki-containing | 2 |
| 197 | mdg-1-diabetic | 1 |
| 198 | medel | 2 |
| 199 | medial-dose | 1 |
| 200 | median-dose | 2 |
| 201 | mediterranean-diet | 1 |
| 202 | mein | 10 |
| 203 | menicare | 2 |
| 204 | meta-meth-oxy | 2 |
| 205 | methane-sulfonamyl | 1 |
| 206 | methane-sulfonyl | 1 |
| 207 | methoxyimino | 1 |
| 208 | methylsulfamoyl | 1 |
| 209 | mi-untreated | 1 |
| 210 | mid-trial | 9 |
| 211 | mild-monotherapy | 1 |
| 212 | mim-only | 1 |
| 213 | min.each | 1 |
| 214 | mixed-disability | 2 |
| 215 | mk-801+risperidone | 1 |
| 216 | mmvc | 1 |
| 217 | monofluoroalkyl | 1 |
| 218 | monophylogenetic | 1 |
| 219 | morphine-benzedrine | 2 |
| 220 | motivation/skills | 1 |
| 221 | mtx-vimang | 3 |
| 222 | mtx/res | 1 |
| 223 | multi-disciplinal | 1 |
| 224 | multi-single-specialty | 1 |
| 225 | multiplayer | 8 |
| 226 | n-dimethylaminophenyl | 1 |
| 227 | naf-treated | 1 |
| 228 | nch3 | 1 |
| 229 | ndg-treated | 1 |
| 230 | nhpc | 3 |
| 231 | no-boost | 2 |
| 232 | no-catheter-use | 1 |
| 233 | no-metformin | 1 |
| 234 | no-morbidity | 1 |
| 235 | no-pmdi | 1 |
| 236 | no-pop | 2 |
| 237 | no-prompt | 7 |
| 238 | no-relaxant | 1 |
| 239 | no-rest | 1 |
| 240 | no-retransfusion | 1 |
| 241 | no-supply | 1 |
| 242 | nocardia-treatment | 1 |
| 243 | non-ams | 3 |
| 244 | non-antisiphon | 8 |
| 245 | non-at | 1 |
| 246 | non-bisoprolol | 1 |
| 247 | non-cilostazol | 1 |
| 248 | non-cin | 3 |
| 249 | non-crossover | 8 |
| 250 | non-drain | 1 |
| 251 | non-enalapril | 1 |
| 252 | non-gel | 1 |
| 253 | non-haart | 3 |
| 254 | non-interview | 1 |
| 255 | non-microalbuminuria | 1 |
| 256 | non-niddk | 1 |
| 257 | non-oh | 5 |
| 258 | non-parallel | 3 |
| 259 | non-pemetrexed-containing | 2 |
| 260 | non-postmature | 1 |
| 261 | non-ppv | 1 |
| 262 | non-sbo | 1 |
| 263 | non-taboo | 1 |
| 264 | nonconcomitant | 3 |
| 265 | noncrossover | 5 |
| 266 | nonpolymerized | 1 |
| 267 | nontamoxifen-containing | 1 |
| 268 | nontransported | 1 |
| 269 | normalisized | 1 |
| 270 | normo-trained | 1 |
| 271 | not-improved | 2 |
| 272 | np-training | 1 |
| 273 | nvp/cbv | 1 |
| 274 | o'-carboxylate | 3 |
| 275 | o1a2 | 2 |
| 276 | o2a1 | 2 |
| 277 | on-licensed | 1 |
| 278 | one-arm | 22 |
| 279 | oral+vaginal | 1 |
| 280 | osteo-induced | 2 |
| 281 | ovx+epi | 1 |
| 282 | oxygen-resuscitated | 1 |
| 283 | p+en | 7 |
| 284 | p-nsai | 1 |
| 285 | p1032 | 2 |
| 286 | pa-etched | 2 |
| 287 | paired-matched | 3 |
| 288 | paliperidone-er | 2 |
| 289 | pantihose | 1 |
| 290 | parallel | 5,919 |
| 291 | parallel- | 3 |
| 292 | pc-3/smac | 3 |
| 293 | peer-drinking | 1 |
| 294 | phentolaminum | 3 |
| 295 | phenylhydrazido | 1 |
| 296 | phono | 5 |
| 297 | phycocyanin-fed | 1 |
| 298 | pilates-exercise | 1 |
| 299 | placebo-control | 66 |
| 300 | placebo-precedence-treated | 1 |
| 301 | placebo-therapy | 1 |
| 302 | placebo/no-treatment | 1 |
| 303 | placebo/pseudo-placebo | 1 |
| 304 | pleg | 2 |
| 305 | pn+gln | 5 |
| 306 | po-po | 1 |
| 307 | polycan | 7 |
| 308 | poorest-risk | 1 |
| 309 | ppausal | 1 |
| 310 | pra+mica+ | 3 |
| 311 | pra+mica- | 2 |
| 312 | practica | 2 |
| 313 | practitioner-assisted | 1 |
| 314 | pravastatin-treatment | 1 |
| 315 | prescriptions-control | 1 |
| 316 | pro-amed | 2 |
| 317 | project-oriented | 1 |
| 318 | propofol/dexmedetomidine | 6 |
| 319 | propofol/fentanyl | 8 |
| 320 | prp-plus | 2 |
| 321 | psychologist-assisted | 1 |
| 322 | qrhx+mtx | 3 |
| 323 | quasi-control | 1 |
| 324 | quchi+fenglong | 1 |
| 325 | quchi+zhongwan+fenglong | 1 |
| 326 | r286-d96 | 1 |
| 327 | raltitrexed/oxaliplatin | 1 |
| 328 | rd-3d+mi | 1 |
| 329 | reduced-mastication | 1 |
| 330 | regicor2000 | 3 |
| 331 | regul8 | 9 |
| 332 | remi-pro-roc | 1 |
| 333 | remi-pro-rocu | 2 |
| 334 | residential/outpatient | 2 |
| 335 | residual-component | 1 |
| 336 | resistance-band-protocol | 1 |
| 337 | resource-building | 1 |
| 338 | retinopathy/aer | 1 |
| 339 | rixx4414 | 1 |
| 340 | rsv/pi-3-inoculated | 1 |
| 341 | s-apr-treated | 1 |
| 342 | s/as01e | 14 |
| 343 | saline-propofol | 1 |
| 344 | se/cd-treated | 1 |
| 345 | sealant-using | 1 |
| 346 | sec-amino | 1 |
| 347 | self-nominated | 1 |
| 348 | sex-treatment | 3 |
| 349 | sham-sham-treated | 1 |
| 350 | sham‑surgery | 1 |
| 351 | side-by-side | 49 |
| 352 | silica-treated | 6 |
| 353 | silodosin-preceding | 1 |
| 354 | sinecod | 1 |
| 355 | single-cleansing | 4 |
| 356 | slef-treatment | 1 |
| 357 | smp/gmp/g60 | 3 |
| 358 | soy-po | 1 |
| 359 | spi-guided | 7 |
| 360 | statins-treated | 1 |
| 361 | stimuliv-treated | 1 |
| 362 | stonebreaker | 1 |
| 363 | strech | 2 |
| 364 | sub-treatment | 1 |
| 365 | sulfadiazine-trimethoprim | 3 |
| 366 | sulfo | 1 |
| 367 | sulphydril | 1 |
| 368 | sunitinib-containing | 2 |
| 369 | supplement-only | 2 |
| 370 | t2dm-t | 3 |
| 371 | tam-stratified | 1 |
| 372 | tamsulosin-preceding | 1 |
| 373 | tcd-treated | 5 |
| 374 | telophase-like | 1 |
| 375 | temperature-recovery | 1 |
| 376 | tetra-fluoro-phenolate | 1 |
| 377 | thecontrol | 2 |
| 378 | therapy-withdrawal | 2 |
| 379 | thermotolerance/hyperthermia | 6 |
| 380 | thetreatment | 1 |
| 381 | thiopurine-exposed | 1 |
| 382 | three-cycle | 10 |
| 383 | three-parallel | 1 |
| 384 | tibolne | 1 |
| 385 | tibotec-virco | 4 |
| 386 | tigloyl | 1 |
| 387 | time-challenged | 1 |
| 388 | tmz-rt | 3 |
| 389 | toggleloc | 5 |
| 390 | toxin-supplemented | 1 |
| 391 | traditional-reperfusion | 1 |
| 392 | treatment-formulation | 1 |
| 393 | treatment-order | 1 |
| 394 | trenching | 2 |
| 395 | tri-ethnic | 1 |
| 396 | trialon | 1 |
| 397 | trials-the | 4 |
| 398 | trials.no | 6 |
| 399 | trichothiodystrophy | 2 |
| 400 | trigone-only | 1 |
| 401 | tsv/clp | 1 |
| 402 | two-age-class | 1 |
| 403 | two-parallel | 4 |
| 404 | two-post | 1 |
| 405 | tza | 1 |
| 406 | umepamuenas | 1 |
| 407 | undergraduate-entry | 2 |
| 408 | unicore | 7 |
| 409 | unitedhealth | 2 |
| 410 | unstirred | 2 |
| 411 | v-pl-v | 4 |
| 412 | v-v-pl | 2 |
| 413 | vitro/twins | 1 |
| 414 | voxel-wise-based | 1 |
| 415 | vthr | 3 |
| 416 | w-i/r | 2 |
| 417 | wait-control | 5 |
| 418 | wake-sleep | 3 |
| 419 | walk-across | 2 |
| 420 | walking-exercise | 1 |
| 421 | wei-collateral | 1 |
| 422 | well-examined | 1 |
| 423 | well-maintained.patient | 1 |
| 424 | wellness-control | 1 |
| 425 | within-dose | 1 |
| 426 | within-food | 4 |
| 427 | ws070117-treated | 1 |
| 428 | yang-predominant | 1 |
| 429 | yc-1+thermotolerance/hyperthermia | 6 |
| 430 | ydgdr-treated | 6 |
| 431 | yin-predominant | 1 |
| 432 | yoga-and-exercise | 1 |
| 433 | zhongwan+fenglong | 1 |
| 434 | zlt-fed | 1 |
| 435 | zn-treated | 3 |
| 436 | α1,3gti-3 | 5 |
| 437 | β-blocker-3d+mi | 1 |
| 438 | ≃ | 3 |
| 1 | pra+mica+ | 3 |
| 2 | dha+ | 3 |
| 3 | pra+mica- | 2 |
| 4 | parallel- | 3 |
| 5 | into- | 1 |
| 6 | regicor2000 | 3 |
| 7 | smp/gmp/g60 | 3 |
| 8 | lps/mabtrem-1 | 1 |
| 9 | o2a1 | 2 |
| 10 | anti-vefgr1 | 1 |
| 11 | p1032 | 2 |
| 12 | 31/172 | 2 |
| 13 | control_2 | 1 |
| 14 | o1a2 | 2 |
| 15 | α1,3gti-3 | 5 |
| 16 | nch3 | 1 |
| 17 | rixx4414 | 1 |
| 18 | r286-d96 | 1 |
| 19 | e2997 | 2 |
| 20 | regul8 | 9 |
| 21 | ad-ace2+a779 | 2 |
| 22 | ar79 | 3 |
| 23 | practica | 2 |
| 24 | gcea | 5 |
| 25 | thermotolerance/hyperthermia | 6 |
| 26 | yc-1+thermotolerance/hyperthermia | 6 |
| 27 | non-microalbuminuria | 1 |
| 28 | cad-ela | 1 |
| 29 | 'inma | 1 |
| 30 | hfd+haepa | 2 |
| 31 | ir+sa | 1 |
| 32 | tza | 1 |
| 33 | 9a-b | 1 |
| 34 | baseline-hb | 17 |
| 35 | h-ob | 1 |
| 36 | 'club | 1 |
| 37 | pc-3/smac | 3 |
| 38 | tri-ethnic | 1 |
| 39 | htlv-1-asymptomatic | 2 |
| 40 | mdg-1-diabetic | 1 |
| 41 | monophylogenetic | 1 |
| 42 | cma-coc | 2 |
| 43 | dienogest-coc | 2 |
| 44 | toggleloc | 5 |
| 45 | remi-pro-roc | 1 |
| 46 | nhpc | 3 |
| 47 | mmvc | 1 |
| 48 | fxc | 2 |
| 49 | idpn+jpzdd | 2 |
| 50 | counter-balanced | 44 |
| 51 | cryptorchidism-induced | 2 |
| 52 | osteo-induced | 2 |
| 53 | spi-guided | 7 |
| 54 | phycocyanin-fed | 1 |
| 55 | zlt-fed | 1 |
| 56 | time-challenged | 1 |
| 57 | paired-matched | 3 |
| 58 | control-matched | 1 |
| 59 | pa-etched | 2 |
| 60 | tam-stratified | 1 |
| 61 | pro-amed | 2 |
| 62 | normo-trained | 1 |
| 63 | well-examined | 1 |
| 64 | equally-numbered | 1 |
| 65 | unstirred | 2 |
| 66 | voxel-wise-based | 1 |
| 67 | analogue-based | 2 |
| 68 | on-licensed | 1 |
| 69 | thiopurine-exposed | 1 |
| 70 | cold/heat-repressed | 1 |
| 71 | dox-intoxicated | 1 |
| 72 | ws070117-treated | 1 |
| 73 | silica-treated | 6 |
| 74 | linifanib-treated | 1 |
| 75 | se/cd-treated | 1 |
| 76 | tcd-treated | 5 |
| 77 | gsd-treated | 1 |
| 78 | gcae-treated | 5 |
| 79 | placebo-precedence-treated | 1 |
| 80 | isoflavones-berberine-treated | 1 |
| 81 | naf-treated | 1 |
| 82 | crf-treated | 1 |
| 83 | ndg-treated | 1 |
| 84 | sham-sham-treated | 1 |
| 85 | karaya-saponin-treated | 1 |
| 86 | zn-treated | 3 |
| 87 | flp-treated | 3 |
| 88 | ydgdr-treated | 6 |
| 89 | s-apr-treated | 1 |
| 90 | biologics-treated | 1 |
| 91 | statins-treated | 1 |
| 92 | ac-ps-treated | 2 |
| 93 | cs-ps-treated | 1 |
| 94 | galn/lps-treated | 1 |
| 95 | stimuliv-treated | 1 |
| 96 | mi-untreated | 1 |
| 97 | clinician-initiated | 6 |
| 98 | diagnosis-related | 47 |
| 99 | rsv/pi-3-inoculated | 1 |
| 100 | low-toxin-contaminated | 1 |
| 101 | self-nominated | 1 |
| 102 | faculty-moderated | 2 |
| 103 | bis-titrated | 5 |
| 104 | oxygen-resuscitated | 1 |
| 105 | counselor-facilitated | 1 |
| 106 | age-orientated | 1 |
| 107 | project-oriented | 1 |
| 108 | toxin-supplemented | 1 |
| 109 | l-trp-supplemented | 1 |
| 110 | nontransported | 1 |
| 111 | practitioner-assisted | 1 |
| 112 | psychologist-assisted | 1 |
| 113 | not-improved | 2 |
| 114 | nonpolymerized | 1 |
| 115 | equally-sized | 2 |
| 116 | normalisized | 1 |
| 117 | lancefield | 6 |
| 118 | sinecod | 1 |
| 119 | within-food | 4 |
| 120 | high-reward | 3 |
| 121 | s/as01e | 14 |
| 122 | country-race | 1 |
| 123 | half-side | 6 |
| 124 | side-by-side | 49 |
| 125 | trials-the | 4 |
| 126 | india.the | 2 |
| 127 | telophase-like | 1 |
| 128 | all-male | 4 |
| 129 | bioconjugatable | 1 |
| 130 | three-cycle | 10 |
| 131 | jinsane | 7 |
| 132 | clomi-phene | 1 |
| 133 | propofol/dexmedetomidine | 6 |
| 134 | iri+saline | 1 |
| 135 | dexmedetomidine-atropine | 3 |
| 136 | morphine-benzedrine | 2 |
| 137 | inventory-morphine-benzedrine | 1 |
| 138 | difluorine | 1 |
| 139 | bromo-phenyl-piperazine | 1 |
| 140 | 3-methylpiperazine | 1 |
| 141 | tibolne | 1 |
| 142 | mk-801+risperidone | 1 |
| 143 | acetaminophen/oxycodone | 2 |
| 144 | chemotherapyalone | 1 |
| 145 | 3-ketone | 1 |
| 146 | menicare | 2 |
| 147 | unicore | 7 |
| 148 | non-postmature | 1 |
| 149 | yoga-and-exercise | 1 |
| 150 | walking-exercise | 1 |
| 151 | pilates-exercise | 1 |
| 152 | medial-dose | 1 |
| 153 | median-dose | 2 |
| 154 | within-dose | 1 |
| 155 | pantihose | 1 |
| 156 | no-catheter-use | 1 |
| 157 | tetra-fluoro-phenolate | 1 |
| 158 | o'-carboxylate | 3 |
| 159 | flute | 6 |
| 160 | 'dialogue | 2 |
| 161 | hsp-negative | 1 |
| 162 | fixed-size | 3 |
| 163 | catheter-size | 1 |
| 164 | bdf/f | 1 |
| 165 | ganirelix-mf | 2 |
| 166 | hul+17-aag | 4 |
| 167 | pleg | 2 |
| 168 | 0.05-mg | 1 |
| 169 | ir+ng | 1 |
| 170 | mtx-vimang | 3 |
| 171 | silodosin-preceding | 1 |
| 172 | tamsulosin-preceding | 1 |
| 173 | resource-building | 1 |
| 174 | trenching | 2 |
| 175 | peer-drinking | 1 |
| 176 | diet-plus-resistance-training | 1 |
| 177 | combined-exercise-training | 1 |
| 178 | np-training | 1 |
| 179 | k-134-containing | 1 |
| 180 | sunitinib-containing | 2 |
| 181 | celecoxib-containing | 1 |
| 182 | non-pemetrexed-containing | 2 |
| 183 | highest-dose-containing | 1 |
| 184 | matki-containing | 2 |
| 185 | nontamoxifen-containing | 1 |
| 186 | afo-wearing | 7 |
| 187 | single-cleansing | 4 |
| 188 | 5-htt-expressing | 1 |
| 189 | sealant-using | 1 |
| 190 | ginger-receiving | 2 |
| 191 | quchi+fenglong | 1 |
| 192 | zhongwan+fenglong | 1 |
| 193 | quchi+zhongwan+fenglong | 1 |
| 194 | ins+/-rsg | 1 |
| 195 | min.each | 1 |
| 196 | strech | 2 |
| 197 | cidr-heatsynch | 2 |
| 198 | keyswitch | 2 |
| 199 | abciximab/ufh | 1 |
| 200 | cd163high | 3 |
| 201 | non-oh | 5 |
| 202 | gth | 3 |
| 203 | unitedhealth | 2 |
| 204 | hp-cvvh | 6 |
| 205 | p-nsai | 1 |
| 206 | no-pmdi | 1 |
| 207 | low-protein/high-gi | 3 |
| 208 | bushenhuatanyizhi | 1 |
| 209 | rd-3d+mi | 1 |
| 210 | acei-3d+mi | 1 |
| 211 | β-blocker-3d+mi | 1 |
| 212 | bw-bmi | 2 |
| 213 | ovx+epi | 1 |
| 214 | himawari | 2 |
| 215 | clp+xbj | 1 |
| 216 | hhpg-19k | 4 |
| 217 | non-niddk | 1 |
| 218 | hf-10-week | 1 |
| 219 | '4-week | 1 |
| 220 | '26-week | 1 |
| 221 | poorest-risk | 1 |
| 222 | mid-trial | 9 |
| 223 | control-trial | 3 |
| 224 | oral+vaginal | 1 |
| 225 | multi-disciplinal | 1 |
| 226 | wei-collateral | 1 |
| 227 | ppausal | 1 |
| 228 | therapy-withdrawal | 2 |
| 229 | medel | 2 |
| 230 | non-gel | 1 |
| 231 | parallel | 5,919 |
| 232 | 2-parallel | 2 |
| 233 | 3-parallel | 1 |
| 234 | 4-parallel | 1 |
| 235 | balanced-parallel | 1 |
| 236 | three-parallel | 1 |
| 237 | non-parallel | 3 |
| 238 | two-parallel | 4 |
| 239 | clopdogrel | 1 |
| 240 | etc.sildenafil | 1 |
| 241 | sulphydril | 1 |
| 242 | non-enalapril | 1 |
| 243 | resistance-band-protocol | 1 |
| 244 | saline-propofol | 1 |
| 245 | non-bisoprolol | 1 |
| 246 | quasi-control | 1 |
| 247 | intervention-control | 11 |
| 248 | placebo-control | 66 |
| 249 | prescriptions-control | 1 |
| 250 | wellness-control | 1 |
| 251 | wait-control | 5 |
| 252 | thecontrol | 2 |
| 253 | 5-fu-sol | 2 |
| 254 | non-cilostazol | 1 |
| 255 | v-v-pl | 2 |
| 256 | guanidyl | 1 |
| 257 | dimethoxymethyl | 1 |
| 258 | monofluoroalkyl | 1 |
| 259 | methane-sulfonamyl | 1 |
| 260 | propofol/fentanyl | 8 |
| 261 | n-dimethylaminophenyl | 1 |
| 262 | cycloalkenyl | 1 |
| 263 | keto-carbonyl | 1 |
| 264 | 2-methoxy/ethoxycarbonyl | 1 |
| 265 | methane-sulfonyl | 1 |
| 266 | tigloyl | 1 |
| 267 | methylsulfamoyl | 1 |
| 268 | 3-chloro-2-hydroxypropyl | 2 |
| 269 | 9-aryl | 1 |
| 270 | epoxystearyl | 1 |
| 271 | 2'/3'-o-acetyl | 2 |
| 272 | and-phenylpentyl | 1 |
| 273 | carbamoylheptyl | 1 |
| 274 | 2-hy-droxy-3-methyl-benzyl | 1 |
| 275 | 3-chloro-6-hy-droxy-2,4-di-methyl-benzyl | 1 |
| 276 | 2-methoxy-5-chlorobenzyl | 1 |
| 277 | 3-chloro-4-methoxybenzyl | 1 |
| 278 | sulfadiazine-trimethoprim | 3 |
| 279 | im/pm | 2 |
| 280 | one-arm | 22 |
| 281 | phentolaminum | 3 |
| 282 | polycan | 7 |
| 283 | bipartisan | 1 |
| 284 | irbesatan | 2 |
| 285 | p+en | 7 |
| 286 | manual-driven | 2 |
| 287 | betwen | 1 |
| 288 | imatinib+ifn | 1 |
| 289 | non-drain | 1 |
| 290 | non-cin | 3 |
| 291 | mein | 10 |
| 292 | no-metformin | 1 |
| 293 | diabetes/metformin | 1 |
| 294 | raltitrexed/oxaliplatin | 1 |
| 295 | double-dose-statin | 1 |
| 296 | ezetimib/simvastatin | 1 |
| 297 | pn+gln | 5 |
| 298 | non-antisiphon | 8 |
| 299 | traditional-reperfusion | 1 |
| 300 | no-retransfusion | 1 |
| 301 | reduced-mastication | 1 |
| 302 | low-radiation | 4 |
| 303 | treatment-formulation | 1 |
| 304 | clinic-invitation | 1 |
| 305 | before-implementation | 1 |
| 306 | experimenter-verbalization | 1 |
| 307 | long-detection | 1 |
| 308 | adherence-intervention | 1 |
| 309 | trialon | 1 |
| 310 | 6-electron | 1 |
| 311 | heterokaryon | 2 |
| 312 | placebo/pseudo-placebo | 1 |
| 313 | non-sbo | 1 |
| 314 | tibotec-virco | 4 |
| 315 | cresco | 5 |
| 316 | formamido | 3 |
| 317 | phenylhydrazido | 1 |
| 318 | sulfo | 1 |
| 319 | trials.no | 6 |
| 320 | sec-amino | 1 |
| 321 | benzyl-amino | 1 |
| 322 | methoxyimino | 1 |
| 323 | phono | 5 |
| 324 | non-taboo | 1 |
| 325 | po-po | 1 |
| 326 | soy-po | 1 |
| 327 | 5-nitro | 1 |
| 328 | anodal-so | 3 |
| 329 | diabetes-bp | 1 |
| 330 | wake-sleep | 3 |
| 331 | tsv/clp | 1 |
| 332 | gcop | 1 |
| 333 | no-pop | 2 |
| 334 | imrt-tp | 8 |
| 335 | groups-r | 1 |
| 336 | w-i/r | 2 |
| 337 | paliperidone-er | 2 |
| 338 | retinopathy/aer | 1 |
| 339 | treatment-order | 1 |
| 340 | bite-wafer | 1 |
| 341 | stonebreaker | 1 |
| 342 | high-performer | 1 |
| 343 | low-performer | 1 |
| 344 | ferrer | 3 |
| 345 | before/after | 56 |
| 346 | non-crossover | 8 |
| 347 | noncrossover | 5 |
| 348 | multiplayer | 8 |
| 349 | khr | 2 |
| 350 | conhr | 1 |
| 351 | vthr | 3 |
| 352 | match-pair | 2 |
| 353 | ch2or | 1 |
| 354 | umepamuenas | 1 |
| 355 | hs+hes | 11 |
| 356 | mallet-osteotomes | 1 |
| 357 | mtx/res | 1 |
| 358 | chair-rises | 2 |
| 359 | internal-fire+phlegm-dampness+blood-stasis | 2 |
| 360 | motivation/skills | 1 |
| 361 | non-ams | 3 |
| 362 | vitro/twins | 1 |
| 363 | co-immunizations | 2 |
| 364 | hydrofibers | 2 |
| 365 | inter-observers | 2 |
| 366 | two-age-class | 1 |
| 367 | walk-across | 2 |
| 368 | prp-plus | 2 |
| 369 | hippopotamus | 2 |
| 370 | t2dm-t | 3 |
| 371 | non-at | 1 |
| 372 | mediterranean-diet | 1 |
| 373 | 3dcrt+ht | 3 |
| 374 | gh/hmg/gnrhant | 3 |
| 375 | yang-predominant | 1 |
| 376 | yin-predominant | 1 |
| 377 | nonconcomitant | 3 |
| 378 | no-relaxant | 1 |
| 379 | 20-patient | 4 |
| 380 | 35-patient | 1 |
| 381 | 9-patient | 1 |
| 382 | forty-patient | 1 |
| 383 | well-maintained.patient | 1 |
| 384 | residential/outpatient | 2 |
| 385 | nocardia-treatment | 1 |
| 386 | sub-treatment | 1 |
| 387 | late-treatment | 8 |
| 388 | slef-treatment | 1 |
| 389 | pravastatin-treatment | 1 |
| 390 | placebo/no-treatment | 1 |
| 391 | hot-treatment | 2 |
| 392 | sex-treatment | 3 |
| 393 | thetreatment | 1 |
| 394 | residual-component | 1 |
| 395 | controlled-point | 1 |
| 396 | no-prompt | 7 |
| 397 | tmz-rt | 3 |
| 398 | non-haart | 3 |
| 399 | delayed-start | 29 |
| 400 | information-support | 2 |
| 401 | no-rest | 1 |
| 402 | no-boost | 2 |
| 403 | two-post | 1 |
| 404 | remi-pro-rocu | 2 |
| 405 | anbainou | 1 |
| 406 | v-pl-v | 4 |
| 407 | nvp/cbv | 1 |
| 408 | non-ppv | 1 |
| 409 | non-interview | 1 |
| 410 | h-nw | 1 |
| 411 | h-ow | 1 |
| 412 | cycle/ue-ex | 2 |
| 413 | qrhx+mtx | 3 |
| 414 | trichothiodystrophy | 2 |
| 415 | trigone-only | 1 |
| 416 | mim-only | 1 |
| 417 | bt-only | 1 |
| 418 | booklet-only | 2 |
| 419 | supplement-only | 2 |
| 420 | crt-only | 1 |
| 421 | no-supply | 1 |
| 422 | placebo-therapy | 1 |
| 423 | mild-monotherapy | 1 |
| 424 | sham‑surgery | 1 |
| 425 | temperature-recovery | 1 |
| 426 | undergraduate-entry | 2 |
| 427 | cystitis-injury | 3 |
| 428 | gutsy | 1 |
| 429 | no-morbidity | 1 |
| 430 | mixed-disability | 2 |
| 431 | high-mobility | 36 |
| 432 | equivalence/noninferiority | 3 |
| 433 | multi-single-specialty | 1 |
| 434 | meta-meth-oxy | 2 |
| 435 | flx/olz | 1 |
| 436 | ≃ | 3 |
| 437 | icd† | 1 |
| 438 | colinox® | 1 |